RecruitingNCT06544629

Imjudo & Imfinzi PMS

Imjudo & Imfinzi Post-Marketing Surveillance

Sponsor

AstraZeneca

Enrollment

246 participants

Start Date

Apr 14, 2025

Study Type

OBSERVATIONAL

Conditions

Hepatocellular Carcinoma

Summary

Based on the re-review of new drugs article, Korean pharmaceutical act, the objectives of this study are to assess safety and effectiveness of the study drugs(Imjudo \& Imfinzi) in a real world setting in patients who treated according to the approved indications in Korea.

Eligibility

Plain Language Summary

Simplified for easier understanding

This is a post-marketing surveillance study in South Korea monitoring the real-world safety and effectiveness of two immunotherapy drugs — tremelimumab (Imjudo) and durvalumab (Imfinzi) — in patients who are already approved to receive them. **You may be eligible if...** - You are a patient in South Korea who qualifies for tremelimumab or durvalumab according to the approved label - You are able to provide signed informed consent **You may NOT be eligible if...** - You are using these drugs for an off-label (unapproved) indication - You are currently participating in another clinical intervention trial Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.